#384 - Special episode — Obicetrapib: The CETP inhibitor with cardiovascular benefits and potential Alzheimer's prevention

What It Covers

Peter Attia examines obicetrapib, a CETP inhibitor drug that lowers LDL cholesterol by 30–60% on top of existing statin therapy, and analyzes the Broadway biomarker study showing it significantly attenuates p-tau 217 progression — a key Alzheimer's marker — with the strongest signal in APOE4 homozygous carriers.

Key Questions Answered

• •CETP inhibitor history: Four predecessor drugs failed for two distinct reasons: off-target toxicity (torcetrapib raised blood pressure; anacetrapib accumulated in fat cells) or insufficient ApoB reduction despite large HDL increases. Obicetrapib avoids both failure modes, producing 30–60% LDL reductions and 16–30% ApoB reductions on top of maximum statin therapy in phase two and three trials.
• •LP(a) reduction mechanism: Obicetrapib reduces Lp(a) by approximately one-third, likely by decreasing synthesis of apolipoprotein(a), the protein component that combines with LDL to form Lp(a) particles. This matters because Lp(a) affects one in eight to one in twelve people and is otherwise extremely difficult to modify through existing therapies or lifestyle interventions.
• •APOE4 brain lipid dysfunction: Carriers of one or two APOE4 alleles produce a structurally altered apoE protein due to a single amino acid substitution (cysteine to arginine at position 112), making brain cholesterol transport less efficient. This lipid trafficking impairment accelerates Alzheimer's pathology by roughly two decades in homozygous APOE4 carriers compared to APOE3 homozygotes.
• •Broadway biomarker findings: In the Broadway sub-study of 1,500 participants, obicetrapib reduced p-tau 217 progression from 5% to 2% across all participants over 12 months. In the 29 APOE4 homozygous participants specifically, placebo showed a 12.7% increase while obicetrapib produced a nearly 8% decrease — a statistically significant 20-percentage-point difference across all measured Alzheimer's biomarkers.
• •HDL-brain barrier mechanism: Small, lipid-poor HDL particles carrying apoA-1 can cross the blood-brain barrier in limited quantities. CETP inhibition increases circulating apoA-1 concentration, potentially augmenting cholesterol efflux within the CNS and partially compensating for the dysfunctional apoE-mediated lipid trafficking that characterizes APOE4 carriers — offering a plausible biological explanation for the observed biomarker effects.